1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD) is named after the German physiologist who first presented neuropathological characteristics of the dementia at the 37th meeting of Society of Southwest German Psychiatrists in 1906 \[[@B1]\]. Alzheimer\'s studied a patient with progressive memory loss for five years and analyzed the brain post mortem using silver staining \[[@B2]\]. This contributed to the identification of neuritic plagues and neurofibrillary tangles (NFT) \[[@B1]\], two characteristics employed to identify the dementia to date. It took another 20 years to determine *β*-amyloid (A*β*) and tau which are major components of neuritic plagues and NFTs, respectively \[[@B3]\], marking the modern era of study of AD research.

AD, as a progressive neurodegenerative disorder, deprives patients of their memory and even lives. Memory loss is the most notable symptom \[[@B4], [@B5]\] at the early stage but as the disorder advances, difficulties with language, perception, and execution of movement become prominent \[[@B6]\], followed by neuropsychiatric and behavioral abnormality, muscle mass loss, and mobility deterioration \[[@B6]\]. Loss of normal daily living in those with dementia is inevitable.

In addition to the affliction and sufferings to patients, Alzheimer\'s disease can cost society substantially, especially in developed countries. The expenditure of AD was around \$100 billion per year \[[@B7]\]; the bill was about €177 billion in Europe solely in 2008 \[[@B8]\]. Due to deteriorating abilities to live on their own, caregivers are necessary for progressed AD patients. Burdens on these caregivers\' life including physical, psychological, and economic aspects \[[@B9]--[@B11]\] can be a major concern.

The global prevalence of dementia for people over the age of 60 is estimated as high as 40 million in 2001, and the figure is forecasted to double every 20 years \[[@B12], [@B13]\], indicating that Alzheimer\'s disease has become a modern epidemic. In the near future, surging number of AD patients will become an overbearing social issue. Therefore, the need for therapeutic strategies for this devastating disease is urgent.

Currently, Food and Drug Administration (FDA) approved AD drugs are still limited within two categories: cholinesterase inhibitors and memantine \[[@B14]--[@B16]\] (a NMDA receptor antagonist). Unfortunately, the effects and benefits of these drugs are marginal and work only to alleviate the symptoms \[[@B17]--[@B19]\]. However, in recent years, fundamental researches focusing on the pathogenesis of AD paved the way for development of new treatments targeting the radical source of Alzheimer\'s disease \[[@B20]\]. Numerous trials have been or are currently being conducted to determine effects of various compounds on AD in different stages.

Alzheimer\'s disease causes major impairment of individual health and social economy due to the limited effective therapeutic approaches. With the explosive explorations based on two hallmarks of AD, numerous clinical trials targeting on or off A*β* have been or are being conducted. In this paper, we will briefly summarize successes and failures in clinical trials in Alzheimer\'s disease and try to give a systematic review in an attempt to derive insights from previous experience.

2. Therapeutic Targets Focusing on A*β* Cascade Hypothesis ([Table 1](#tab1){ref-type="table"}) {#sec2}
===============================================================================================

2.1. Inhibition of A*β* Production {#sec2.1}
----------------------------------

Studies of familial Alzheimer\'s disease (FAD) motivate the discovery of responsible genetic factors, establishing A*β*-centered theory for AD. Amyloid precursor protein (APP) experiences sequential cleavages by *β*-secretase and *γ*-secretase and gives rise to the dementia culprit *β* amyloid (A*β*) that is thought to initiate soluble oligomers, insoluble fibrils, and accumulated plagues ([Figure 1](#fig1){ref-type="fig"}). APP can be alternatively processed by *α*-secretase within the A*β* region and generate a longer C-terminal fragment under the first cleavage. In terms of curbing production of A*β*, the three crucial enzymes processing APP have been therapeutic targets in drug development. The rationale is to inhibit *β*-/*γ*-secretase while promoting the *α*-secretase activity to become the priority strategy.

### 2.1.1. *β*-Secretase (BACE1) Inhibitor {#sec2.1.1}

Beta-site APP-cleaving enzyme 1 (BACE1) is the protease responsible for the initial cleavage of APP, giving rise to the production of neurotoxic suspect A*β* \[[@B21], [@B22]\]. Mounting evidence corroborate the availability of BACE1 inhibition. BACE1 knock-out mice indicated a close correlation between the BACE1 inhibition and the A*β* decline \[[@B23], [@B24]\]. It is reported that BACE1 inhibition improved memory deficits \[[@B25]\] and rescued A*β*-driven cholinergic dysfunction \[[@B26]\] in APP transgenic mice. Although the BACE1-deficient animal model presented a relatively benign phenotype with high viability, suggesting that the possibility of targeting *β*-secretase would be a safe therapeutic approach, further testing indicated that the drastic inhibition would result in hypomyelination and behavioral abnormalities such as seizures \[[@B27]--[@B30]\]. This is because, except from APP, BACE1 has a series of substrates, like neuregulin-1, related to myelination \[[@B29], [@B31]\]. AD pathology onset was postponed in the APP × BACE1+/− mice; however, it hinted at a partial inhibition that might mitigate the potential safety problems \[[@B32], [@B33]\]. It has been noted that the discrepancy between potency-required molecular weight and CNS penetration-required size \[[@B34], [@B35]\] poses another challenge.

Many BACE1 inhibitors are derived from approved drugs for type 2 diabetes with properties regulating insulin metabolism. Nuclear peroxisome proliferator activated receptor gamma (PPAR*γ*) functions as a transcription factor regulating gene expression \[[@B36]\], modulating inflammation response, promoting microglia-mediated A*β* endocytosis, and declining cytokine secretion \[[@B37]\]. Thiazolidinediones can activate PPAR*γ* to inhibit *β*-secretase and promote ubiquitination to degrade amyloid load \[[@B38]\]. PPAR*γ* agonists like thiazolidinediones derivatives rosiglitazone and pioglitazone soften the peripheral insulin resistance \[[@B39]\], which aggravates AD neuropathology, and this decline of insulin sensitivity helps in A*β* proteolysis. The study of rosiglitazone has been developed to a large phase 3 trial; however, it has been discontinued due to cardiac risk concerns \[[@B40]\]. Pioglitazone has recently progressed into a phase 3 clinical trial after precluding a previously reported bladder risk. But due to the involvement of substrate complexity and some adverse effects, other phase 3 clinical trials for BACE1 inhibitors are still lacking.

However, several novel drugs are currently under investigation. Based on conjugation to a penetrant carrier peptide \[[@B41], [@B42]\], the potent CNS impermeable compound, CTS-21166, has completed the phase 1 trial. It showed a good tolerance and a reduction of plasma A*β* level in healthy volunteers \[[@B43]\]. A phase 1b dose-escalating study for MK-8931 demonstrated a positive effect in reducing the level of toxic proteins in addition to safety and good tolerance. A phase 2 trial recruiting 200 mild-to-moderate patients was expanded to a larger 1960-participant phase 3 trial, including conventional cognitive and functional primary outcomes, and it recently passed an interim safety evaluation.

Another BACE1 inhibitor, LY2886721, though it appeared to be safe and lowered A*β*42 in cerebrospinal fluid by more than two-thirds in phase 1 trial \[[@B44]\], was terminated due to the fact that 4 out of 45 patients showed liver abnormalities during the phase 2 trial. Besides, RG-7129 was also terminated in its phase 3 trials in 2013. These terminations again signaled that significant challenges are remaining: whether BACE1 inhibitors will be safe in the long run and if lowering BACE1 activity will slow cognitive decline.

### 2.1.2. *γ*-Secretase Inhibitors (GSI) and Modulators (GSM) {#sec2.1.2}

*γ*-secretase is a transmembrane protease responsible for the eventual cleavage of amyloid precursor protein (APP) to generate A*β* ([Figure 1](#fig1){ref-type="fig"}), thus it is considered a principal therapeutic target in Alzheimer\'s disease \[[@B45], [@B46]\]. This enzyme complex consists of four components: Aph1, Pen2, glycosylated nicastrin, and endoproteolyzed presenilin as the catalytic core \[[@B47]\], and it is involved in myriads of physiological process. The versatility places hurdles in the way of *γ*-secretase targeted drug development. In the human body, aside from APP, there are more than 50 different substrates that *γ*-secretase is capable of reacting with, many of which are neuronal substrates \[[@B48]\]. Importantly, *γ*-secretase is also responsible for cleavage of Notch 1, which leads to the release of the Notch intracellular domain (NICD), subsequently translocated to the nucleus to regulate genes involved in cell development, cell survival, and cell fate determination \[[@B49]\]. Thus, inhibition of *γ*-secretase needs to be cautiously designed to particularly circumvent the drawbacks caused by Notch signaling abnormality. Haematological \[[@B50]\] and gastrointestinal \[[@B51]\] toxicity, skin reactions \[[@B52], [@B53]\], and changes to hair color \[[@B54]\] are the most commonly reported adverse effects of *γ*-secretase inhibitor.

Several *γ*-secretase inhibitors (GSIs) have been launched in clinical trials. Many reduced the A*β* production in plasma or CSF (cerebrospinal fluid), but few successfully avoided the Notch-induced side-effects. Semagacestat decreases A*β* level in plasma and downregulates its generation in the central nervous system (CNS) \[[@B55]\]. Semagacestat is the first *γ*-secretase inhibitor that have been taken into Phase 3 clinical trials. While phase 1 trial suggested a dose-dependent decline of A*β* synthesis in CSF \[[@B55]\], phase 2 trial began exhibiting skin-related side effects. Although A*β* level in plasma has significantly decreased, it was not duplicated in CSF and no effects on cognition and function were found. Two pivotal phase 3 trials were reluctantly started; however they were discontinued due to increased risk of skin cancer and infection and lack of efficacy \[[@B56]\]. Fall of semagacestat, a potentially promising drug candidate, repeated disappointing results of other GSIs, which deemed that a deeper understanding of interaction between 4 subunits and their substrates is necessary.

Different GSIs present favor to interact with subunits of *γ*-secretase, exhibiting target specificity. DAPT and L685458 indicated the smallest selectivity, while MRK-560 and sulfonamide based GSIs strongly prefer to inhibit PS1 instead of PS2 \[[@B57], [@B58]\]. Aph1 heterogeneity is critical for individual survival, suggesting that targeting of Aph1b *γ*-secretase specifically would be more tolerated \[[@B59]\], although the feasibility of drug design still remains difficult to determine.

Accordingly, the second generation Notch-sparing *γ*-secretase inhibitors aimed at selective inhibition of specific sites took the spotlight. Avagacestat (BMS-708163), begacestat, and NIC5-15 are such Notch-sparing GSIs under clinical trials. It was reported that avagacestat (BMS-708163) has 137-fold selectivity for APP over Notch in cell culture and robustly reduces CSF A*β* levels without causing Notch-related toxicity in rats and dogs, although this is still being researched \[[@B60]\]. Phase 2 trials have to be terminated due to the adverse effects of gastrointestinal and dermatological system in addition to the lack of cognitive improvement compared to placebo counterparts. Begacestat decreased the A*β* concentration in the plasma but not in CSF \[[@B49], [@B61]\], and a phase 1 clinical trial in combination with cholinesterase inhibitor donepezil has been completed, further data was unavailable. Another Notch sparing GSI candidate, NIC5-15, a natural monosaccharide \[[@B62]\], is currently under a phase 2 trial and demonstrated good tolerance and safety \[[@B63]\].

Given that the unresolved adverse effects brought on by GSIs are tricky to address, the concept of *γ*-secretase modulators (GSMs) was established with the expectation of nonsteroidal anti-inflammatory drugs (NSAIDs). A subset of NSAIDs, like ibuprofen, indomethacin, and sulindac sulfide, disconnected from their cyclooxygenase (COX) properties were discovered to be able to selectively reduce the production of A*β*42 at the cost of elevated shorter peptide A*β*38 \[[@B64], [@B65]\]. Surprisingly, this downregulation of toxic A*β* level lacks the inhibitory effect on Notch or other substrates \[[@B64]\]. This finding promoted the GSMs as promising therapeutic candidates for Alzheimer\'s disease, because the Notch-induced drawbacks may be avoided and on the other hand, the overproduction of shorter and more soluble A*β*38 seems less likely to aggregate and is less pathogenic.

Among the compounds described above, tarenflurbil (R-flurbiprofen) relates to ibuprofen structurally and pharmacologically. Phase 1 trials with a broad dose range (400 to 1600 mg/day) revealed a low drug exposure in the brain \[[@B66]\], while phase 2 trials narrowed this spectrum (400--800 mg, twice daily) and showed trivial benefits on function with the lowest dosage (400 mg). Although undesirable side effects like nausea, dizziness, and diarrhea were observed, this compound is still considered tolerable \[[@B67]\]. After modification, phase 3 trial suggested neither functional improvement nor clinical efficacy in the mild AD patients \[[@B68]\] and thus the results were disappointing. The weak potency of tarenflurbil can be attributable to low CNS penetration as shown in phase 1 trial, and on the other hand, NSAID residue activity curbed A*β* clearance mechanism mediated by microglia \[[@B69]\].

Another GSM CHF-5074 based on R-flurbiprofen ameliorated brain A*β* load and improved the animals\' performance in behavior tests. The drug\'s safety and tolerability have been evaluated and are undergoing a phase 2 trial. Published data indicated that this compound may have an additional function of acting independently of A*β*42 \[[@B71], [@B72]\]. Nevertheless, a balance between lipophilicity and potency of these compounds must be considered. The remarkably increased potency in 2nd and 3rd generations of GSMs relies heavily on the increase of lipophilicity, which has been proved to result in off-targets, like hepatotoxicity \[[@B73]\].

### 2.1.3. *α*-Secretase Activator {#sec2.1.3}

APP can be cleaved by an alternative *α*-secretase rather than *β*-secretase in the first step to circumvent the generation of pathological A*β* peptide. Hence, increasing the chance of *α*-cleavage could be an effective approach to decrease the A*β* formation and promote soluble APP production to protect neurons \[[@B74]\]. Agonists of muscarinic, glutamate, and serotonin receptors (and the agonists or antagonists of transmitters receptors would be discussed in following section), statins, oestrogens, testosterone, and protein kinase C activators belong to this drug classification that can motivate *α*-secretase activity, and they have been launched in clinical trials, but data indicating their use in AD is limited \[[@B75]\].

Etazolate (EHT-0202), a selective GABA~A~ \[[@B76]\] receptor modulator, has completed a phase 2 trial in patients with mild to moderate AD. It presented a good oral bioavailability and an elevation of sAPP*α* \[[@B77]\]. Bryostatin-1, a macrocyclic lactone, caused a decline of brain A*β*40/42, improved behavior test in AD mouse model \[[@B78]\], and was under a phase 2 trial, but the specific information is inaccessible.

Statin drugs such as atorvastatin and simvastatin lower peripheral cholesterol production to prevent heart attacks and other expressions of cardiovascular disease. Atorvastatin, in combination with cholinesterase inhibitor, has completed a phase 2 clinical trial and achieved a beneficial cognition and function \[[@B79]\], but failed to repeat the outcome in a 641-patient phase 3 clinical trial \[[@B80], [@B81]\]. Simvastatin can penetrate BBB and long-term statin treatment can decline A*β* level. In a 35-normal participant phase 4 trial of Simvastatin, it was reported to reduce phospho-tau-181 in CSF, while not total tau or A*β* level \[[@B82]\]. A follow-up study evaluating one year simvastatin treatment in 120 cognitively normal and middle-aged adults, effect on CSF levels of A*β*42, t-tau, and p-tau181, is ongoing.

2.2. Anti-*β*-Amyloid Aggregation {#sec2.2}
---------------------------------

The pathological A*β* peptides, prone to assembly into aggregate as neuro-/synaptic toxic products spur the idea of inhibition of A*β* aggregation or destabilization of the A*β* oligomers species. However, A*β* aggregations are characterized with a high stability resistance to disaggregation \[[@B83]\] and remain insoluble even with heat or SDS \[[@B84]\]. The fact that amyloid fibrils have an extremely low energy state \[[@B83]\] and the lack of thorough understanding of A*β* aggregation process have complicated the issue. Besides, another challenge would be to access the compounds with high CNS bioavailability and low immunogenicity and toxicity. It is generally believed there are three strategies that block A*β* aggregation: antiaggregate compounds, metal complexing agents and immunization. They can disturb the formation of either soluble oligomers or insoluble plagues.

### 2.2.1. Nonpeptidic Antiaggregates {#sec2.2.1}

The first class of mentioned inhibiting aggregation compounds is nonpeptidic antiaggregates, tramiprosate, derived from proprionic acid that is a primitive representative. The promising outcomes of this agent from the safety and tolerance \[[@B85]\] were neutralized by two following phase 3 trials: the European trial precluded methodological problems that might lead to the negative in the North American trial and demonstrated the poor CNS penetration and the weak potency \[[@B86]\] of this drug.

The second generation of nonpeptidic antiaggregates was expected to meet those challenges. Scyllo-inositol is thought to effectively impede A*β* aggregation, promote misfolding modulation, and accelerate aggregates disassociation \[[@B87]\]. Because this compound can cross blood brain barrier (BBB), with the assistance of inositol transporters, it can achieve a high concentration in CNS via peripheral administration. This drug is being tested in the phase 2 trial with mild-to-moderate Alzheimer\'s disease patients on the basis of good tolerance and safety profile \[[@B88]\]. Although high doses (1000 mg and 2000 mg) resulted in serious adverse effects, the studies continued to test the low dose (250 mg) cohorts \[[@B89]\]. Epigallocatechin-3-gallate (EGCg), a polyphenol from green tea, via disrupting unfolded peptide, stimulated *α*-secretase activity and inhibited A*β* aggregation in animal models \[[@B90]\]. This agent was also involved in modulation of cell transduction, regulation of cell survival and death \[[@B90]\], and protection of mitochondrial function. The multiple effects of this natural compound make it a promising candidate, and a phase 3 trial with early AD patients with EGCg is being conducted.

### 2.2.2. Metal Complexing Agents {#sec2.2.2}

After A*β* peptides were produced and released into extracellular fluids, metals like Zn and Cu can motivate oligomerization into fibrils. So metal chelators or metal complexing agents that can interfere with reaction of metal ions with A*β* are likely to be a therapeutic strategy. Clioquinol (PBT2), metal-induced A*β* inhibitors, also has a potent CNS permeability. PBT2 can redistribute metal ions to neurons promoting metalloproteinase expression and thus an increment of A*β* degradation. A phase 2 trial was completed and it proved a decrease of A*β*42 concentration in CSF and an improvement of cognitive and behavioral performance \[[@B91]\].

### 2.2.3. Active Immunization {#sec2.2.3}

It is conventionally thought that clearance of CNS A*β* requires a BBB permeability property, confining the therapeutic targets in a very narrow realm: medicinal chemistry-driven and small molecules. Nonetheless, incredible work done by Schenk et al. revealed that immunization of PDAPP transgenic mice markedly mitigated amyloid plaque burden, improved neuritic dystrophy, and even reduced existed A*β* plagues \[[@B92]\]. This striking breakthrough suggested that A*β* immunotherapy would be a potential strategy to remove both soluble and aggregated *β* amyloid \[[@B93]\].

AN-1792, the first anti-A*β* vaccine (with full length A*β* 1--42) tested in active immunization clinical trial, was terminated in the phase 2 trial in patients with early AD due to the fact that some participants developed aseptic meningoencephalitis and cerebral microhemorrhage \[[@B94]\]. The complication is attributed to cytotoxic T cell or autoimmune response \[[@B95]--[@B97]\]. Therefore, employing only fragments instead of full length of A*β* or other cell epitopes to circumvent toxicity and inflammation is highlighted. Additionally, the security of adjuvant and delivery approaches must be cautiously considered.

The next generation of vaccine is devoid of any T-cell epitopes. CAD-106, consisting A*β* 1--6 peptides coupled to a Q*β* virus-like particle, has recently completed the phase 2 trial in patients with mild AD and did not lead to meningoencephalitis \[[@B98]\]. Two other vaccines, UB 311 (A*β* 1--14) and V950 (A*β* N-terminal conjugated to ISCO-MATRIX), both containing B-cell epitopes, have also recently finished phase 1 trial. However, another vaccine AC-001(A*β* 1--7 conjugated to inactivated diphtheria toxin) discontinued its phase 2 trial in August 2013, because the studied drug elicited a strong antibody response. Another active immunization approach is developed on the foundation of Affitope using short six-amino acid peptides that imitate the native A*β* sequence. AD-01 and AD-02, targeting N-terminal fragments of A*β*, were proved to rescue AD-like symptoms in animal models \[[@B99]\]. Recently, AD-02 has progressed into a phase 2 clinical trial.

### 2.2.4. Passive Immunization {#sec2.2.4}

Another strategy to avoid immune response is direct administration of antibodies. This passive immunization has an approximate potency to remove amyloid plaques and rescue neuritic and glial pathology \[[@B100]\], reduce early tau hyperphosphorylation \[[@B101]\] and cytopathology \[[@B102]\], and reverse abnormal hippocampus synaptic plasticity \[[@B103]\].

Bapineuzumab (AAB-001) is a humanized monoclonal antibody, derived from 3D6, published to promote removal of A*β* plagues and rescue synapse loss in APP transgenic mice brain \[[@B100]\]. However, in a 234-patient phase 2A safety and tolerability trial, this agent indicated no significant alteration on primary measures of cognition and daily activity. For apolipoprotein E (ApoE) *ε*4 carriers, there is a temporary vasogenic oedema, an adverse effect correlated with dose administration \[[@B88]\]. Given that 4,000 mild AD patients across North America and Europe showed no treatment effect on either cognitive or functional outcomes, the phase 3 trial was terminated. Solanezumab (LY2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the A*β* peptide (A*β* 16--24) and designed to specifically bind soluble species of A*β*. Phase 2 study showed dose-dependent increases of various A*β* species in plasma and CSF, an indication that insoluble A*β* is released from plagues and leaches into fluid \[[@B104]\]. Two trials in phase 3 suggested a limited benefit for cognitive performance as compared to cholinesterase-inhibitor drugs. A third trial started from July 2013 to test demonstrated brain amyloid burden, and data is expected to be read out in December 2016. Gantenerumab, a human IgG1 antibody binding to A*β* fibrils, can elicit phagocytosis to remove A*β* plagues in brain and rescue A*β* oligomers that induced impaired long-term potentiation (LTP) in rats model. An expanded phase 2/3 trial of 770 participants is being conducted and is estimated to be completed in 2016. Crenezumab, a novel humanized antibody with IgG4 backbone, is believed to limit microglia mediated inflammatory cytokines release to avoid vasogenic oedema. It can recognize *β* amyloid oligomers, fibrils, and plagues with a high binding affinity. Phase 1 study confirmed safety and tolerance, followed by an ongoing phase 2 trial in patients with mild to moderate AD using elevated dose as well as a test for prevention of this progressive dementia. There are several antibodies which have completed or have undergone the early clinical trials, as shown in [Table 1](#tab1){ref-type="table"}.

Many monoclonal antibodies are delivered intravenously, whereas passive immunization can be also accomplished via infusion of intravenous of immunoglobulins (IVIg) from healthy donor. A small study in 8 patients showed increase of A*β* antibodies in serum, decrease of A*β* in CSF, and stabilization of MMSE (mini-mental-state exam) scores over 18 months. A phase 2 trial with 24 patients suggested beneficial cytokine concentrations alteration in plasma. However, two critical phase 3 trials showed no difference between study drug and placebo, though a trend toward benefit for the higher dose, and thus were halted. Another published phase 2/3 clinical trial evaluating infusion of albumin in combination of IVIg is currently conducted in patients with mild to moderate AD.

Active immunization maintains the body with a constant high concentration of immunoglobulin, so this strategy calls for fewer follow-up injections with a reasonable expense. But to tackle with the T-cell induced inflammation would be a tricky issue. Passive immunization is a more effective method especially for elderly people considering their weakened responsiveness to vaccines \[[@B105]\]. Selection of safe epitopes can be readily met, as well as a better control of antibody titer; however, antibody delivery could be inconvenient and costly, and the risk of vasogenic oedema and cerebral amyloid angiopathy might increase.

2.3. Tau {#sec2.3}
--------

According to A*β* hypothesis, intracellular neurofibrillar tangles (NFTs) induced by altered phosphatase/kinase activity is a downstream event of aggregation of *β*-amyloid ([Figure 1](#fig1){ref-type="fig"}), and NFTs as a catalyst will aggravate the oxidation and further result in neuronal dysfunction, cell death, and transmitter deficits. Tau is normally a highly soluble protein in cytoplasm binding to microtubules as a stabilizer. Formation of NFTs as a result of hyperphosphorylated and misfolded tau protein aggregation is toxic to neurons. The pathological tau proteins lose the capability to aid microtubules in transporting neuronal substance, leading to neuronal dysfunction and apoptosis \[[@B106], [@B107]\].

### 2.3.1. Kinase Inhibitors {#sec2.3.1}

Protein kinase, a group of critical enzymes responsible for tau overphosphorylation, is a prerequisite for the tau-induced toxicity. However, myriads of kinases mutually play a central role in regulating cell function and guaranteeing a normal physiological condition. The development of tau-targeted therapy is therefore challenging due to redundancy of kinase interactions and uncertainty of which enzyme specifically catalyzes the phosphorylation that we are focusing on \[[@B108], [@B109]\].

The first class of tau inhibitors aims to modulate tau phosphorylation via decreasing the activity of related kinase since imbalanced interaction between glycogen synthase kinase 3 beta (GSK3*β*) and protein phosphate 2 (PP2A) enhances tau hyperphosphorylation and NFT formation \[[@B110]\]. GSK3*β* appears to engage in AD pathogenesis given its impact on cellular signaling and gene description \[[@B110]\]. Recently, it has been reported that GSK3*β* is responsible for 31% of the pathological phosphorylation sites of tau protein \[[@B111]\] and is found colocalized with NFTs in postmortem brain \[[@B112], [@B113]\]. Toxic A*β* that promotes GSK3*β* activity bridges a link between the two hallmarks of Alzheimer\'s disease \[[@B111]\], implicating that GSK3*β* inhibitor is a potential drug target.

Lithium and valproate reduced tau phosphorylation and prevented reversed aspects of tauopathy in animal models \[[@B114]\] but did not show cognitive improvement in clinical trials with AD patients \[[@B115]\]. NP-031112 (NP-12), a non-ATP competitive inhibitor of GSK3*β*, counteracts tau phosphorylation, reverses amyloid burden in brain, prevents cell loss, and rescues spatial memory deficits using animal models \[[@B116]\]. But the phase 2b trial was terminated due to the negative results. Development of some paullone, indirubin, and maleimide family-derived GSK3*β* inhibitors is in the pipeline, yet stuck in the preclinical trials concerning the cytotoxic effects.

Cyclin dependent kinase 5 (cdk5) is another kinase tightly associated with tau pathology. Cdk5 regulating protein was found in AD brain and thus is probably causing a pathophysiological tau phosphorylation \[[@B117]\]. Cdk5-selective inhibitors were demonstrated to penetrate BBB and reduce elevated A*β* level by regulating cdk5 \[[@B118]\] and are at preclinical status. The test of several compounds targeting other protein kinases, like cdk1/2/9, p38, Erk1/2, JNK, casein kinase, and DYRKIA brought disappointing outcomes, and trials were discontinued due to the poor efficacy or severe adverse effects.

### 2.3.2. Inhibition of Tau Aggregation {#sec2.3.2}

Another scenario to interfere with tau-induced NFT is to inhibit tau aggregation or promote tau assembly disassociation. Rember (methylene blue) is such a tau antiaggregant \[[@B119]\]. Preclinical data revealed a learning deficit reversing property and a completed phase 2 trial proved that this agent can slow down AD progression with a good bioavailability \[[@B120], [@B121]\]. TRx0237, another methylene blue, has an improved drug absorption, bioavailability, and tolerability. Since 2008, intensive investigation of this agent began, and growing evidence indicated that TRx0237 benefits neuroprotection \[[@B122]\] and A*β* clearance in transgenic mice and improves spatial learning in rats \[[@B120], [@B123]\]. The antiaggregation properties were reported by some papers, and three phase 3 studies are ongoing.

Epothilone D (BMS-241027) is a microtubule stabilizer, via inhibition of tau release from microtubule to maintain the transportation function of axon, and on the other hand, precludes formation of tau aggregation. This agent restored behavioral and cognitive deficits, inhibited neuron loss, and curbed the tauopathy in animal models \[[@B124], [@B125]\]. Epothilone can penetrate BBB and exert a better efficacy at low concentration and now undergoes a phase 1 clinical trial. Nicotinamide, the precursor of coenzyme NAD+, reduces phosphorylated tau and protects microtubules stabilization in mouse model \[[@B126]\]. Nicotinamide has been launched into clinical studies suggesting that it is safe and well tolerated and a phase 2 clinical trial is ongoing in patients with mild-to-moderate Alzheimer\'s disease.

3. Putative Therapies Still Derived from Neurotransmitter System {#sec3}
================================================================

Neurotransmitters depletion (basically referring to acetylcholine, ACh) and synaptic dysfunction are two classical features of AD \[[@B127]\]. Thus, two hypotheses have been established---cholinergic hypothesis \[[@B128]\] and glutamatergic hypothesis \[[@B129]\], based on which FDA approved therapies---AchE inhibitors and NMDA receptor antagonists---to mitigate AD symptoms were developed. Although drugs regulating transmitters\' production, release, and recycling cannot prevent the progression of AD, pursuit of searching novel receptor agonists and antagonists has never stopped ([Table 2](#tab2){ref-type="table"}).

Cholinergic neurons impairment accompanies the early progression of dementia. From animal and human studies, cholinesterase inhibitors administration stimulated memory and learning process \[[@B130]\]. Besides, a marked correlation between loss of cholinergic neurons and deterioration of defected memory was proved in animal models later \[[@B131], [@B132]\]. Therefore, improvement of cholinergic system, including potentiating effects of acetylcholine (Ach) and inhibiting activity of cholinesterase, is a potential therapeutic goal.

Ach is a ligand for nicotine receptors and exerts an excitatory effect on the postsynaptic neuron, an essential event for long-term potentiation (LTP) and memory formation. Several nicotinic receptor agonists to reinforce this event are being tested in clinical trials. EVP-6124, a selective agonist of the *α*-7 nicotinic acetylcholine receptor, has finished a phase 1/2 trial showing safe and well tolerated results and recently (Oct 2013) entered two phase 3 trials to test the cognitive benefits. Quite a few other clinical trials testing nicotinic agonists are ongoing (ladostigil hemitartrate, phase 2; ispronicline, phase 1), completed (RO5313534), or terminated (ABT-089).

A transmitter that indirectly modulates neuron degeneration and memory deficits is serotonin (5-HT). Growing evidence indicated that inhibition of 5-HT~6~ could facilitate Ach release and via elevated cholinergic transmission, memory and learning defects were likely to be ameliorated. 5-HT~6~ antagonists were widely reported in many studies to rescue anticholinergic drugs-induced amnesia \[[@B133]\]. Recently, two agents, PRX-03140(5-HT~4~ antagonist) and SB-742457(5-HT~6~ antagonist), completed the phase 2 trials. Lu AE58054, an antagonist of the serotonin 6 (5-HT~6~) receptor was recently progressed into a phase 3 trial with 930 mild to moderate AD patients in combination with AchE inhibitor donepezil.

4. Potential Findings of Therapeutics for Alzheimer\'s Disease from Other Perspectives {#sec4}
======================================================================================

In addition to the two hallmarks and neurotransmitter system impairment, there are several other features found in Alzheimer\'s disease, including inflammation, oxidative stress, mitochondrial dysfunction, neurotrophin deficiency, and so forth. These aspects are not systematically and thoroughly summarized and are likely to be neglected though; they do provide new perspectives in developing AD treatments. Many drugs of great therapeutic potential are under clinical trials ([Table 3](#tab3){ref-type="table"}).

4.1. Anti-Inflammation and Antioxidants {#sec4.1}
---------------------------------------

Chronic inflammation is an essential feature of AD and contributes to its pathogenesis in numerous ways. Microglia are brain\'s resident macrophages that monitor brain activity and play a contributing role in removal of redundant and apoptotic neurons \[[@B134], [@B135]\], remodeling of normal synapse \[[@B136]\], and protection of CNS from pathogens and detritus \[[@B137]\]. However, they can shift to another phenotype to secrete series of inflammatory factors, exerting detrimental effects on bystander neurons and processes they are involved in. Aggregated A*β* appears to be a robust agent driving this alteration, since markers of activated microglia were densely colocalized within the deposits \[[@B138], [@B139]\]. Microglia seem incapable of degrading A*β* that they intake \[[@B140], [@B141]\], leading to a frustrated phagocytosis instead. As clinical trials have been a major disappointment, agents that drive microglia to a phenotype that favors attack on pathogens rather than bystander neurons may hold therapeutic potential.

Based on compelling evidence of the involvement of inflammation in AD pathogenesis, anti-inflammatory drugs have been investigated. COX inhibitors, aiming to reverse the elevated A*β* burden and cognitive deficits caused by overexpression of COX2 \[[@B142], [@B143]\], showed limited efficacy \[[@B144]\]. Glucocorticoid steroids, considered as potent drugs by declining overexpression of proinflammatory mediators \[[@B145]\], showed poor benefits \[[@B146]\] or adverse effects \[[@B147]\]. Flavonoid administration prevented cognitive impairment associated with inflammation in animal studies \[[@B148], [@B149]\]; however, the beneficial effects cannot be repeated in human \[[@B150]\].

Another anti-inflammatory agent etanercept, an approved arthritis drug, is a TNF-*α* antagonist to neutralize the activated microglia secreted cytokines. Modulation of immune system may have benefits for Alzheimer\'s disease patients and a phase1 clinical trial in combination with supplementation of some specific nutrients is ongoing in mild to moderate AD patients. Curcumin, a natural polyphenol, has anti-inflammatory and antioxidant properties and exhibits other neuroprotective functions like promoting metal chelation, curbing tau aggregation, and facilitating neurogenesis. It undergoes a phase 2 study, but details are not available.

Oxidative injury is the following causal event of inflammation and the study of antioxidants in treatment of AD achieved little success. Alpha-tocopherol, a synthetic vitamin E, is thought to prevent brain cell damage by destroying toxic free radicals and slowing down the cognitive decline in the finished phase 3 trial. In addition, a phase 3 trial of DHA (docosahexaenoic acid), an omega-3 fatty acid, was terminated because cognitive decline was not changed compared to placebo group.

4.2. Mitochondrial Dysfunction {#sec4.2}
------------------------------

Mitochondrial dysfunction taking place in early AD enhances synaptic damages and neuron apoptosis, so it is considered a causal factor of neurodegeneration \[[@B151]\]. APP and A*β* are transported into mitochondrion reacting with mitochondrial components, leading to an impaired ATP processing and increased oxidative stress level \[[@B151], [@B152]\]. ApoE4, a risk factor for sporadic AD, harms mitochondrial trafficking and function and promotes mitochondrial apoptosis \[[@B153], [@B154]\]. Replacing mitochondrial DNA (mtDNA) form one cell line with mtDNA from AD patients supported a mitochondrion cascade hypothesis \[[@B155]\], offering new therapeutic targets. Latrepirdine (dimebon), an antihistamine that preserves mitochondrial structure and function and protects against A*β* induced pore apoptosis, has been tested in a clinical trial in Russia and phase 2 data showed improvement of all outcomes \[[@B156]\] while phase 3 trial did not confirm it \[[@B157]\]. However, a combination of therapy with donepezil was demonstrated as well tolerated from preliminary results in phase 1 trial and further information awaits analysis \[[@B158]\]. AC-1204 is designed to improve mitochondrial metabolism \[[@B159]\] by induction of chronic ketosis, thus rescuing regional cerebral hypometabolism presented in early Alzheimer\'s disease, and this agent is undergoing a phase 3 clinical.

4.3. Diabetes {#sec4.3}
-------------

Diabetes is another risk factor for Alzheimer\'s disease \[[@B160]\] in which the insulin resistance and disrupted glucose metabolism \[[@B161]\] can be attributed to a tumor necrosis factor (TNF) induced inflammation pathway \[[@B162], [@B163]\]. Insulin can mediate A*β* degradation by activating insulin-degrading enzyme (IDE) \[[@B164]\]. A CSF insulin decline in prodromal female AD patients \[[@B165]\], the presence of insulin resistance, and the dysfunctional insulin signaling pathway in dementia brain \[[@B166]\] are documented. Incretin and liraglutide, two drugs for hyperglycemia, implicating beneficial effects on AD mice \[[@B167], [@B168]\], reinforced the relationship between diabetes and AD, and a phase 2 study of liraglutide, a glycogen like peptide 1 agonist is still ongoing. These evidences brought the advent of concept "type 3 diabetes," \[[@B169]\] and an intranasal insulin delivery with an ameliorating cognitive function effect \[[@B170]\] has completed its phase 2 study.

4.4. ApoE (Apolipoprotein) and A*β* Export {#sec4.4}
------------------------------------------

ApoE (apolipoprotein) is a powerful genetic factor \[[@B171], [@B172]\] for sporadic AD beyond APP, PS1, and PS2 genes. The isoform ApoE4 substantially promotes the risk of AD and decreases the age of onset \[[@B173]\]. ApoE is generally thought to regulate A*β* clearance and thus influence fibrillogenesis. In CNS, ApoE, responsible for transportation of cholesterol to neurons, is primarily produced in astrocytes \[[@B174]\]. A*β* aggregation and clearance are differently affected in an isoform (*ε*2, *ε*3, and *ε*4) dependent manner; frequency of AD and mean age at clinical onset are 91% and 68 years of age in *ε*4 homozygote, 47% and 76 years of age in *ε*4 heterozygote, and 20% and 84 years in *ε*4 noncarriers \[[@B173], [@B175]\]. ApoE was found colocalized with amyloid plagues \[[@B176]\] and this coexistence is more abundant in ApoE4 carriers \[[@B177]\]. Additionally, ApoE4 is associated with cognition decline before clinically apparent syndromes \[[@B178], [@B179]\]. ApoE4, as previously described, can work synergically with other risk factors, like insulin resistance and peripheral vascular diseases \[[@B180], [@B181]\], thus exerts a confounding effect on AD and triggers inflammatory cascade. After being synthesized, ApoE is lipidated by the ABCA1, a process regulated by nuclear receptor liver X receptor (LXR) or retinoid X receptor (RXR), and transported to form lipoprotein particles. The complex particle binds soluble A*β*, promoting transfer via neuron surface receptors such as low-density lipoprotein receptor (LDLR), low-density lipoprotein receptor-related protein 1 (LRP1), and heparin sulphate proteoglycan (HSPG) \[[@B182], [@B183]\] into neurons where degradation can be finished with proteolysis in lysosome. ApoE *ε*4 isoform has less affinity of binding A*β* compared to *ε*3, showing a less efficient clearance phenotype \[[@B184], [@B185]\]. Stimulation of LXR/RXR enhances removal of A*β* \[[@B186], [@B187]\] while inhibition of ABCA1 impairs A*β* clearance in ApoE4 rather than ApoE3 mice \[[@B188]\]. Therefore, the molecules and receptors involved in ApoE metabolism can be potential therapeutic targets for drug development.

Recent studies demonstrated that oral administration of bexarotene, a RXR agonist and a FDA approved anticancer drug, reduces A*β* plaques and improves cognitive function in an ApoE-dependent manner in amyloid mouse model \[[@B187]\], and a phase 2 clinical trial is currently ongoing to determine its safety and effect on abnormal proteins in the brain with 300 mg for one month compared to placebo. Other drugs that aim to regulate ApoE expression (LXR agonist TO901317) \[[@B186], [@B189]\], block ApoE-A*β* interaction, disrupt ApoE4 domain (CB9032258, phthalazinone analogue) \[[@B190]\], mimic the receptor binding region \[[@B191]\] (COG112), and so forth, have shown benefits of reversing A*β* burden in vivo or in vitro, but did not reach the clinical trials yet. ApoE-targeted therapies are still at the early stage of development and relevant approaches and strategies are required to carefully evaluate them though, showing a huge promising battle with Alzheimer\'s disease.

4.5. Neurotrophin {#sec4.5}
-----------------

Nerve growth factor (NGF) as a neurotrophin plays a critical role promoting survival and maintaining the function of cholinergic neurons \[[@B192], [@B193]\]. In AD patients, transcription and translation levels of NGF were changed \[[@B194], [@B195]\], suggesting that NGF supplementation probably is a treatment approach for Alzheimer\'s disease. NGF with unfavorable size and polarity is a peptide that cannot cross BBB \[[@B194], [@B196]\], so to safely and efficiently deliver it to the brain will be a great challenge \[[@B197], [@B198]\]. However, efforts have been made to overcome this obstacle. An example of strategy is as follows: CERE-110 uses adeno-associated virus to transfer a gene that makes NGF and is injected into AD patients\' brain. This approach undergoes a phase 2 study.

5. Concluding Remarks {#sec5}
=====================

A*β* cascade hypothesis was firstly proposed in 1992 \[[@B199]\] assuming that *β*-amyloid would be the suspect initiating pathogenesis of Alzheimer\'s disease. So a series of explorations focusing on physiological and pathological processes that participate in the production, aggregation, and clearance of A*β* have been widely studied. The identification of two crucial enzymes (*γ*-secretase and BACE1), responsible for the cleavage of the presumably pathogenic A*β* from its precursor, suggests that the cure of AD may be around the corner.

However, failures in many large clinical trials using A*β*-targeted drugs ([Table 4](#tab4){ref-type="table"}) and FDA approved compounds with marginal efficacy questioned the validity of A*β* cascade hypothesis. Indeed, A*β* hypothesis, having dominated the AD realm for two decades, has always been controversial. One of the most unfavorable evidences was the finding that amyloid plagues were diffused in AD patients\' brain postmortem (and neuroimaging outcomes confirmed the autopsy findings), which is abundant in healthy people \[[@B200], [@B201]\]. Nevertheless, plenty subsequent investigations put forward the oligomeric form of A*β*, rather than plagues, as the actual culprit for synapse dysfunction \[[@B202], [@B203]\] and the following amplifying events. This significant finding, at least partially, defended the validity of A*β* cascade hypothesis. But, still, why do therapeutic strategies targeting the secretases only have marginal efficacy? First, the two versatile secretases (BACE1 and *γ*-secretase) are at the same time responsible for processing other substrates, which unfortunately are either vital to metabolism normality or tricky to avoid targeting. The undesirable side effects are so overwhelming that they prohibit drug\'s efficacy and approval. Second, the drug permeability through blood brain barrier (BBB) is another considerable problem. Most drugs described above have a poor capability to cross BBB, so it is reasonable to see numerous clinical trials, including those having progressed to phase 3, fail. Instead of questioning the plausible hypothesis, it is more imperative to cautiously design clinical studies and interpret the outcomes.

Given limited benefits from inhibition of A*β* production, more focus should be converted to the clearance strategy. Delivery of antibodies may be a good choice due to the safety leverage compared to vaccine. Besides, there are quite a few ongoing clinical trials using passive immunization. From [Table 1](#tab1){ref-type="table"}, antibodies are capable of binding and clearing multiple forms of A*β*. It is important because there is equilibrium between oligomers and plagues of A*β* \[[@B204]\]. For a single-target antiaggregate disrupting formation or enhancing disassembly of A*β* oligomers, plagues as a reservoir will replenish and maintain the balance \[[@B205], [@B206]\]. So the property of simultaneously interfering different processes during A*β* aggregation suggested that passive immunization might be of a promising value.

In recent years other AD risk factors have been widely studied. Though no groundbreaking outcomes have been shown, it provided quite a few unprecedented opportunities. First, the validated AD specific biomarkers need to be carefully developed and examined. Biomarkers should be able to at least precisely indicate the response to therapeutic intervention to avoid misinterpretation of clinical trial data. Besides, current animal models have serious limitations. Most transgenic mouse models published in AD studies overproduce A*β* solely mimicking familial Alzheimer\'s disease, might not suffice phenotypes of sporadic AD accounting for the dominant populations.

In addition, AD is a disorder that is too intricate and too factor-driven to be entirely understood from its pathogenesis. As we discussed previously, various factors (A*β*, tau, inflammation, and apoE) complicatedly interact with each other. So the conventional "one protein, one drug, one disease" hypothesis would not work for Alzheimer\'s disease. From the successful experience in therapeutic development in multifactorial diseases like AIDS, atherosclerosis, cancer, and depression, multitarget drugs or combination therapy can possibly generate more benefits. Since drugs with more than one target could possibly mitigate a redundancy effect in such a complex nerve network, this combination therapy or similar approach multitarget-directed ligands (MTDLs) might bring new hope in search of therapeutics for Alzheimer\'s diseases \[[@B207], [@B208]\]. In this novel fashion, some combinations with approved drug are under clinical trials (Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}, RCTs marked with ∗).

Notwithstanding these challenges, with more scientific insights from basic researches and cooperation between laboratories and pharmaceutical companies, it is very likely to find the optimum treatment for Alzheimer\'s disease in the near future.
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![*β*-amyloid hypothesis based therapeutic targets. APP, after sequentially being cleaved by BACE1 and *γ*-secretase, gives rise to a neuron toxic molecule A*β*42. This peptide can exist as monomers or aggregates into oligomers and plagues. The assembly of A*β*42 triggers downstream effects and induces tau phosphorylation. BACE1 inhibitors and GSI/GSM aim to prohibit the production of pathological A*β*, and vaccines or A*β* antibodies promote clearance mechanism. As for tau, GSK-3*β* inhibitors and other antiaggregates are potential therapeutics targeting on blocking tau hyperphosphorylation or aggregation.](BMRI2014-837157.001){#fig1}

###### 

RCTs based on β-amyloid in recent years.

  Mechanism                           RCT                                Status                Estimated end           Dementia stage     Enrollment                     Duration                                                                       Reported outcomes                                                                                             Details of drugs/RCTs
  ----------------------------------- ---------------------------------- --------------------- ----------------------- ------------------ ------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  ↓Aβ production                                                                                                                                                                                                                                                                                                                                                       
   BACE1 inhibitor                    Pioglitazone                       Phase 2; completed    2005.1                  Mild-to-moderate   25                             18 months                                                                                                                                                                                    Insulin sensitizer, class of PPARγ agonists
  CTS-21166                           Phase 1; completed                 2008.2                Healthy                 56                                                                                                                                                                                                                                             
  MK8931                              Phase 3; ongoing                   2018.3                Mild-to-moderate        1960               ≈6.5 years                                                                                                    With enhanced BBB permeability                                                                                
  E2609                               Phase 1; completed                 2013.9                MCI/mild AD             65                                                                                                                                                                                                                                             
   GSI/GSM                            NIC5-15                            Phase 2; ongoing      2013.12                                    40                                                                                                                                                                                                                          Notch-sparing, insulin-sensitizer
  Begacestat                          Phase 1; completed                 2009.10               Elder healthy           49                                                Dose-dependent changes in plasma Aβ levels                                     Selectively inhibits cleavage of APP over Notch \[[@B209]\]                                                   
  CHF 5074                            Phase 2; completed                 2012.4                MCI                     96                 12 weeks                                                                                                      NSAID                                                                                                         
  EVP-0962                            Phase 2; completed                 2013.10               MCI/early stage         52                 14 days                                                                                                                                                                                                                     
   α-secretase activator              Atorvastatin                       Phase 3; completed∗   2007.7                  Mild-to-moderate   600                            80 weeks                                                                                                                                                                                     Tested with AchEI
  Simvastatin                         Phase 3; completed                 2007.10               Mild-to-moderate        400                18 months                                                                                                                                                                                                                   
  Etazolate                           Phase 2a; completed                2009.8                Mild-to-moderate        159                                               Safe and well tolerated                                                        ↑α-secretase activity, acting as a GABA-A receptor modulator and a PDE-4 inhibitor \[[@B210]\]                
  Epigallocatechin-3-gallate (EGCg)   Phase 2/3; ongoing                 2015.6                Early stage             50                 18 months                                                                                                     Prevents the Aβ aggregation via binding to the unfolded peptide                                               
   ↓Aβ aggregation/oligomers          Scyllo-inositol (ELND005/AZD103)   Phase 2; completed    2010.5                  Mild-to-moderate   350                            18 months                                                                      Insufficient to support/refute benefits \[[@B211]\]                                                            
  Tramiprosate (3APS)                 Phase 3                            unknown               Mild-to-moderate        950                                               Suggesting disease-modifying effects \[[@B212]\]                                                                                                                                             
  PBT2                                Phase 2; completed                 2007.12               Mild AD                 80                 12 weeks                       Well-tolerated, ↓CSF Aβ42, and improved executive function \[[@B213]\]                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                      
  ↑A*β* clearance                                                                                                                                                                                                                                                                                                                                                      
   Active immunotherapy               Affitope AD02                      Phase 2; completed    2013.12                 Early stage        335                            \>1 year                                                                                                                                                                                     N-terminal Aβ1-6, a synthetic peptide
  Affitope AD03                       Phase 1; completed                 2011.11               Mild-to-moderate        28                                                                                                                               i.h. with or without adjuvant aluminum                                                                        
  UB 311                              Phase 1; completed                 2011.4                Mild-to-moderate        19                                                                                                                               N-terminal Aβ1-14                                                                                             
  V 950                               Phase 1; completed                 2012.1                                        86                                                                                                                               formulated on Aluminum-containing adjuvant                                                                    
  CAD 106                             Phase 2; completed                 2012.12               Mild AD                 177                                               A favourable safety profile \[[@B214]\]                                        N-terminal Aβ1-6; i.m. of adjuvanted CAD106;                                                                  
   Passive  immunotherapy             BAN2401                            Phase 2; ongoing      2016.12                 MCI/mild AD        800                            18 months                                                                                                                                                                                    mAb against Aβ oligomers
  BIIB037                             Phase 1; ongoing                   2014.11               Prodromal to mild       160                                                                                                                              Administered via intravenous (IV) infusions in subjects                                                       
  Ponezumab                           Phase 2; completed                 2011.8                Mild-to-moderate        198                24 months                                                                                                                                                                                                                   
  Crenezumab                          Phase 2/3; ongoing                 2016.5                Mild-to-moderate        361                24 months                                                                                                                                                                                                                   
  Gammagard (IVIg)                    Phase 2, completed                 2010.4                Mild-to-moderate        24                 6 months                       Improved cognition                                                                                                                                                                           
  Phase 3; completed                  2012.12                            Mild-to-moderate      390                     70 weeks           Showed no significant effect                                                                                                                                                                                                
  Phase 2; ongoing                    2014.10                            MCI                   50                      24 months                                                                                                                                                                                                                                      
  AMBAR                               Phase 2/3; ongoing                 2016.12               Mild-to-moderate        350                                                                                                                                                                                                                                            
  Gantenerumab                        Phase 3; ongoing                   2019.3                Mild                    1000               \>5 months                     Phase 1 RCT↓brain Aβ; high doses, AE                                           Mainly targets Aβ plagues                                                                                     
  Solanezumab                         Phase 3; ongoing                   2016.12               Mild                    2100                                              No benefits in primary outcomes                                                Mainly targets soluble oligomeric Aβ                                                                          
  AAB-003                             Phase 1; ongoing                   2014.8                Mild-to-moderate        104                52 weeks                                                                                                      Previously treated with AAB-003                                                                               
  GSK933776                           Phase 1; completed                 2011.5                                        50                                                                                                                                                                                                                                             
  SAR228810                           Phase 1; ongoing                   2015.1                Mild-to-moderate        48                 14.5--22 months                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                      
  Anti-tau                                                                                                                                                                                                                                                                                                                                                             
   ↓tau production                    Valproate                          Phase 3; complete     2009.12                 Mild-to-moderate   313                            2 years                                                                        Did not show cognitive benefits and prevention of behavioral defects; associated with reduced brain volumes    
  Lithium                             Phase 2; ongoing                   2019.4                                        80                                                A pilot study was insufficient to support or refute the efficacy \[[@B215]\]                                                                                                                 
   ↓tau  fibrillization/deposition    Nicotinamide                       Phase 1/2; ongoing    2014.7                  Mild-to-moderate   50                             24 weeks                                                                                                                                                                                     Vitamin B3
  TRx0237                             Phase 3; ongoing                   2015.12               Mild/mild-to-moderate   700/833            18 months/15 months                                                                                                                                                                                                         
  Methylene blue (Rember)             Phase 2; completed                                       Mild-to-moderate        321                6 months                       Showed uncertain results                                                                                                                                                                     
  Davunetide (AL108)                  Phase 2; completed                 2008.1                MCI                     144                12 weeks                       Showed benefits on memory                                                                                                                                                                    
  BMS-241027                          Phase 1; completed                 2013.10               Mild                    40                 9 weeks                                                                                                                                                                                                                     

RCT: randomized controlled trial; PPAR: peroxisome proliferators activated receptor; BBB: blood brain barrier; MCI: mild cognitive impairment; GSI: *γ* secretase inhibitor; GSM: *γ* secretase modulator; NSAID: nonsteroidal anti-inflammatory drugs; AChEI: acetylcholinesterase inhibitor; GABA: *γ*-aminobutyric acid; PDE: phosphodiesterase; CSF: cerebrospinal fluid; i.h.: subcutaneous injection; i.m.: intramuscular injection; mAb: monoclonal antibody; AE: adverse event.

∗RCTs with a combination of another drug.

Data sources: <http://www.clinicaltrials.gov/>.

###### 

RCTs targeting neurotransmitter systems in recent years.

  Mechanism                      RCT                   Status                 Estimated end      Dementia stage     Enrollment     Duration                             Reported outcomes                                                        Details of drugs/RCTS
  ------------------------------ --------------------- ---------------------- ------------------ ------------------ -------------- ------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------------------------
  Cholinergic agents                                                                                                                                                                                                                              
   AchE inhibitor                Huperzine A           Phase 2/3; completed   2012.6             Mild-to-moderate   390            6 months                             ↑cognitive function, daily living activity, global clinical assessment   A natural AChEI; antioxidant and neuroprotective properties \[[@B216]\]
  Ladostigil hemitartrate        Phase 2; ongoing      2016.9                 MCI                200                36 months                                           Antioxidant properties; modulates APP processing                         
   Nicotinic receptor  agonist   EVP-6124              Phase 3; ongoing       2017.7             Mild-to-moderate   790            26 weeks                             Positive outcomes in a 24-week phase 2b RCT                               
  RO5313534                      Phase 2; completed    2010.11                Mild-to-moderate   389                6 months                                            *α*7 nicotinic receptor agonist; as add-on therapy to donepezil          
  Ispronicline (AZD3480)         Phase 2; ongoing      2014.7                 Mild-to-moderate   300                1 year                                              *α*4*β*2 and *α*2*β*2 nicotinic receptor agonist                         
  MT-4666                        Phase 2; ongoing      2015.5                 Mild-to-moderate   450                24 weeks                                                                                                                     
  ABT-089                        Phase 2; terminated   2013.10                Mild-to-moderate   434                24 weeks                                                                                                                     
  MK-7622                        Phase 2b; ongoing     2017.8                 Mild-to-moderate   830                12--24 weeks   As adjunctive therapy to donepezil   *α*7 receptor modulator                                                  
                                                                                                                                                                                                                                                 
  Glutamatergic agents           AVP-923               Phase 2; ongoing       2014.9             Mild-to-moderate   200            10 weeks                             Behavioral problems                                                      NMDA receptor antagonist
                                                                                                                                                                                                                                                 
  Serotoninergic agents          Lu AE58054            Phase 3; ongoing∗      2016.1             Mild-to-moderate   ≈2500                                               Positive results in a phase 2 RCT, 278 participants, 6 months;           Several phase3 RCTS with donepezil (AchEI);
  SB-742457                      Phase 2; completed    2011.8                 Mild-to-moderate   684                6 months       showed positive results                                                                                       

RCT: randomized controlled trial; AChEI: acetylcholinesterase inhibitor; MCI: mild cognitive impairment; NMDA: N-methyl-D-aspartic acid.

Data sources: <http://www.clinicaltrials.gov/>.

∗RCTs with a combination of another drug.

###### 

Other novel approaches in AD clinical trials.

  Mechanism                              RCT                              Status               Estimated end      Dementia stage     Enrollment   Duration                                    Reported outcomes                                                              Details of drugs/RCTS
  -------------------------------------- -------------------------------- -------------------- ------------------ ------------------ ------------ ------------------------------------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------------------
  Anti-inflammation and antioxidation    Curcumin                         Phase 2; completed   2007.12            Mild-to-moderate   33                                                                                                                                      NSAID, cholesterol-lowering properties
  Etanercept                             Phase 1; ongoing                 2015.6               Mild-to-moderate   12                 12 months    ↑cognitive function with other nutrients.   Approved drug for arthritis; may modulate immune system; benefit AD patients   
  dl-alpha-tocopherol (vitamin E)        Phase 3; completed               2012.10              Mild-to-moderate   613                                                                                                                                                        
  PUFA                                   Phase 1/2; ongoing∗              2015.1                                  100                18 months                                                Tested alone or together with lipoic acid                                      
  RO4602522                              Phase 1; completed               2013.5                                  17                                                                                                                                                         
                                                                                                                                                                                                                                                                             
  PDE inhibitors                         PF-04447943                      Phase 2, completed   2010.9             Mild-to-moderate   198                                                                                                                                     Selective PDE 9A inhibitor
  MK0952                                 Phase 2; completed               2007.11              Mild-to-moderate                                                                               Selective PDE 4 inhibitor                                                      
  Cilostazol                             Phase 4; completed               2013.7               Mild-to-moderate   46                                                                          PDE3 inhibitor, Antiplatelet agent in WMHI; ↑pCREB                             
                                                                                                                                                                                                                                                                             
  Tyrosine kinase inhibitor              Masitinib                        Phase 3; ongoing∗    2015.12            Mild-to-moderate   396                                                                                                                                     In combination with AChEI and/or memantine
                                                                                                                                                                                                                                                                             
  Insulin and GLP1-R agonists            Intranasal insulin (glulisine)   Phase 2/3; ongoing   2015.2             MCI/mild AD        240          12 months                                                                                                                   
  Exendin-4 (exenatide)                  Phase 2; ongoing                 2016.7               MCI/early stage    100                3 years      Showed neuroprotection                      Diabetes agent                                                                 
  Liraglutide                            Phase 2; ongoing                 2017.1               early stage        206                12 months                                                                                                                               
                                                                                                                                                                                                                                                                             
  Modulating mitochondrial function      AC-1204                          Phase 2/3; ongoing   2015.1             Mild-to-moderate   480          26 weeks                                                                                                                    
  Latrepirdine (Dimebon)                 Phase 3; completed               2009.12              Mild-to-moderate   598                6 months                                                                                                                                
                                                                                                                                                                                                                                                                             
  RXR agonist                            Bexarotene                       Phase 2; ongoing     2014.3             Mild-to-moderate   20                                                                                                                                      Approved anticancer drug; linked to key pathways relevant to AD and A*β*
                                                                                                                                                                                                                                                                             
  NGF delivery                           CERE-110                         Phase 2; ongoing     2014.12            Mild-to-moderate   50           24 months                                   24 months                                                                      Designed to help neurons function better; uses a virus to transfer NGF gene
  Encapsulated Cell biodelivery of NGF   Phase 1b                         2011.12                                 6                  12 months                                                                                                                               

RCT: randomized controlled trial; NSAID: nonsteroidal anti-inflammatory drugs; PDE: phosphodiesterase; WMHI: subcortical vascular disease; pCREB: phosphorylated cAMP-response element binding protein; AChEI: acetylcholinesterase inhibitor; GLP1-R: glucagon-likepeptide1 receptor; MCI: mild cognitive impairment; RXR: retinoid X receptors; NGF: nerve growth factor.

∗RCTs with a combination of another drug.

Data sources: <http://www.clinicaltrials.gov/>.

###### 

Terminated trials targeting A*β* hypothesis.

  Mechanism            RCT                      End      Enrollment   Duration                                                                                                                                                          Main reasons
  -------------------- ------------------------ -------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  BACE1 inhibitor      Rosiglitazone            2009.2   693          24 weeks                                                                                                                                                          Unimproved cognitive status
  LY2886721            2013.8                   128                   AE: 4 cases of liver damage in a phase 2 study in June 2013                                                                                                       
                                                                                                                                                                                                                                        
  GSI/GSM              Semagacestat             2011.5   164          \>7 months                                                                                                                                                        Unimproved cognitive status, but worsening functional ability; AE: skin cancers and infections
  Avagacestat          2010.6                   209      24 weeks     AE: gastrointestinal and dermatological abnormalities like diarrhea, nausea, vomiting, rash, and itching skin; nonmelanoma skin cancers; and worsened cognition   
  tarenflurbil         2008.5                   1684     18 months    Insufficient pharmacodynamics: poor capability to penetrate the BBB                                                                                               
                                                                                                                                                                                                                                        
  Active immunology    AN1792                   2003.9   375                                                                                                                                                                            AE: 6 patients developed aseptic meningoencephalitis due cytotoxic T cell response in phase 2a trial
  ACC-001              2014.2                   126      24 months    Showed a serious side effect in phase 2 trial                                                                                                                     
                                                                                                                                                                                                                                        
  Passive immunology   Bapineuzumab (AAB-001)   2012.6   1331         18 months                                                                                                                                                         Showed no treatment effect on either cognitive or functional outcomes in two phase 3 trials
                                                                                                                                                                                                                                        
  GSK3*β* inhibitor    Tideglusib (NP12)        2012.6   306          45 weeks                                                                                                                                                          Missed its primary endpoint and some secondary endpoints

RCT: randomized controlled trial; AE: adverse event; BBB: blood brain barrier.

Data sources: <http://www.clinicaltrials.gov/>; <http://www.alzforum.org/>.
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